UK Neuro Forum will focus on services and support for neuro conditions 28 November 2024: Andrew Gwynne MP, Parliamentary Under-Secretary of State at the Department of Health and Social Care, has announced today that a new UK Neuro Forum will be set up to find ways to improve care and support for people affected by…
Category: Uncategorised
Role of hippocampus in skilled movement control
Researchers at the University of Birmingham have uncovered a surprising role 26 September 2024: Researchers at the University of Birmingham have uncovered a surprising role of the hippocampus – linking this part of the brain to the control of skilled actions such as handwriting, typing, and playing music. The hippocampus is traditionally associated with memory…
Digital therapies for tic disorders
NICE are performing a technology assessment to look at digital enabled therapy for tic disorders in children and young people NICE will assess digital therapies for tic disorders in children and young people to determine whether they can be recommended for use in the NHS, based on the available evidence and cost-saving potential. They are…
Could shared medical appointments increase patient engagement?
New research from ESMT Berlin finds that shared medical appointments increase engagement from patients as they ask more questions, make more comments, and exhibit higher levels of nonverbal engagement, providing greater value for other patients in the sessions. One-on-one service delivery is often considered ideal, with individualised attention assumed to improve client outcomes. In shared service delivery,…
Seer partners with NHS hospitals
Seer partners with NHS hospitals to deliver cloud-based video-EEG-ECG monitoring services that enhance the efficiency of neurology and neurophysiology teams. Seer supports the integration of home-based diagnostics into current clinical workflows through the Seer Home service, a range of home video telemetry offerings. Hospitals can access customised services — including patient set-up, home-based monitoring, data…
Eisai submits a marketing authorisation application (MAA) for lecanemab
Eisai has submitted a Marketing Authorisation Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia) with confirmed amyloid pathology in the brain,1 to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. This…
Karger Publishers Launches its Fourth Annual Vesalius Innovation Award to Advance the Future of Science
For the fourth consecutive year, Karger Publishers is seeking top-of-the-line applicants for its Vesalius Innovation Award. The award is aimed at early-stage startups in the Health Sciences and Publishing sectors that are developing innovative technological solutions with a significant impact in their respective fields. This year marks the fourth year of the Vesalius Innovation Award,…
NICE Recommends Reimbursement for Translarna™
Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy PTC Therapeutics, Inc. today (19/1/23) announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales. Translarna is the…
Ipsen at the World Congress for Neurorehabilitation
Ipsen had a robust presence at the 12th World Congress for Neurorehabilitation (WCNR) in Vienna, Austria and virtually, from 14-17 December 2022, further demonstrating the company’s long-standing partnership with the World Federation for Neurorehabilitation (WFNR) and ongoing commitment to neuroscience. In addition to showcasing the company’s latest neuroscience clinical data, Ipsen hosted a satellite symposium…